Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …
Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell …
The New England Journal of Medicine | Research & Review Articles …
Aug 30, 2025 · The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide …
Antibiotic Treatment for 7 versus 14 Days in Patients with …
Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In …
Lepodisiran - The New England Journal of Medicine
Mar 30, 2025 · Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small …
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
Apr 23, 2025 · In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl …
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a …
Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 16).
Encorafenib, Cetuximab, and mFOLFOX6 in - The New England …
May 30, 2025 · First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF …
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with …
Mar 1, 2025 · Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but …
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for …
Sep 16, 2025 · Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity.